NASDAQ, BMRN - Biomarin Pharmaceuticals
BioMarin Pharmaceutical Inc. (BioMarin, the Company, we or our) develops and
commercializes innovative biopharmaceuticals for serious diseases and medical
conditions. We select product candidates for diseases and conditions that
represent a significant unmet medical need, have well-understood biology and
provide an opportunity to be first-to-market or offer a significant benefit over
existing products. Our product portfolio is comprised of three approved products
and multiple investigational product candidates. Approved products include
Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride) and Aldurazyme
(laronidase).
We are conducting clinical trials on several investigational product candidates
for the treatment of genetic diseases including: PEG-PAL, formerly referred to
as Phenylase? (phenylalanine ammonia lyase), an enzyme substitution therapy for
the treatment of phenylketonurics who are not responsive to Kuvan. ...
Read SEC Filing on NASDAQ.com »